Quick Facts

• Condition Addressed: High blood pressure (Hypertension).
• Therapeutic Purpose: Supports the maintenance of blood pressure within a target range.
• Use Context: May be administered to adults whose blood pressure is not sufficiently managed by a single medication.

---

What Amval Treats: Main Uses and Benefits

Amval is an approved medication intended for the treatment of high blood pressure, a medical condition also known as hypertension. It is typically prescribed to adult patients to assist in achieving and maintaining blood pressure control.

This medication may be used in two primary contexts:

1. Add-on Therapy: It may be introduced to support individuals whose blood pressure levels are not adequately addressed by monotherapy (treatment with a single agent).
2. Initial Therapy: Healthcare professionals may initiate treatment with Amval when there is a clinical likelihood that a patient may require more than one drug to reach their established blood pressure targets.

Maintaining appropriate blood pressure levels is part of a comprehensive strategy for cardiovascular risk management. By contributing to a reduction in blood pressure, Amval may reduce the risk of nonfatal cardiovascular events, including heart attack and stroke.

Regulatory References

1. FDA therapeutic overview

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult patients with essential hypertension.

Populations for whom use is contraindicated (Absolute Ban):

• Patients with known hypersensitivity to Amlodipine, Valsartan, or any dihydropyridine derivatives.
• Patients in the second or third trimesters of pregnancy. If pregnancy is detected, use must be discontinued immediately.
• Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.
• Patients experiencing severe hypotension or a state of shock.
• Patients with specific cardiovascular conditions, such as obstruction of the outflow tract of the left ventricle.
• Patients with diabetes mellitus or renal impairment who are concurrently receiving aliskiren-containing products.

Age and Condition-Specific Eligibility Rules:

• Pediatric Use: Safety and efficacy have not been established in children and adolescents below 18 years of age; therefore, use is not recommended.
• Geriatric Patients: Use in elderly patients (ge 65 years) requires caution.
• Organ Function: Use is restricted and requires caution in patients with mild to moderate hepatic impairment or renal impairment (GFR > 30 mL/min/1.73 m^2). Use is either contraindicated or not established in severe renal impairment.
• Lactation: Use is not recommended while breastfeeding; the decision is to discontinue either the drug or nursing.

Connection to the overall eligibility profile: Regulatory documents establish clear boundaries for the use of this medicine by classifying populations as approved, restricted, or absolutely prohibited. Eligibility is strictly defined by factors including reproductive status, age, known hypersensitivity, and the severity of pre-existing conditions affecting the liver or kidneys.

Interactions with other medicines and products

The official interaction profile for Amval is strictly defined by the regulatory constraints of its two active components, Amlodipine and Valsartan.

Contraindicated and High-Risk Combinations

Co-administration of the Valsartan component with Aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73m^2), due to documented increases in the risk of hypotension and hyperkalemia. The dual blockade of the Renin-Angiotensin System (RAS) by combining Amval with ACE Inhibitors is officially not recommended.

Exposure-Modifying Interactions

The co-administration of Simvastatin with Amlodipine increases Simvastatin systemic exposure, which requires a regulatory restriction that the Simvastatin dose must not exceed 20 mg daily. Strong inhibitors of the CYP3A4 enzyme may increase Amlodipine plasma concentrations, while CYP3A4 inducers may reduce them; this includes substances like Grapefruit and St. John's Wort.

Additive Pharmacodynamic Effects

Co-use with potassium-sparing diuretics or potassium supplements carries a formal risk of hyperkalemia (elevated serum potassium levels) due to an additive pharmacodynamic effect with the Valsartan component. Additionally, co-administration with NSAIDs may reduce the antihypertensive effect and increase the risk of renal function deterioration.

Amval functions as a potent, non-steroidal, selective inhibitor of the farnesyl pyrophosphate synthase (FPPS) enzyme within the mevalonate pathway. Following cellular uptake, Amval concentrates within osteoclasts, where it disrupts the production of isoprenoid lipids, specifically farnesyl pyrophosphate and geranylgeranyl pyrophosphate. This inhibition prevents the prenylation of small guanosine triphosphate (GTPases) signaling proteins, such as Ras, Rho, and Rac, which are essential for osteoclast function and survival.

The lack of prenylation impairs the necessary membrane localization and activity of these GTPases, leading to the disruption of cytoskeletal organization (ruffled border formation) and induction of apoptosis (programmed cell death) in the osteoclasts. By inducing osteoclast apoptosis and reducing their functional capacity, Amval modulates the balance of bone remodeling toward the formation side, resulting in a net physiological effect of reducing excessive bone resorption activity.

How to Use Amval: Official Administration Guidelines

Amval is a fixed-dose combination tablet intended solely for oral administration in the long-term management of high blood pressure. This medicine is taken once daily to maintain consistent control of blood pressure.

Dosing and Frequency

Dosage is expressed as milligrams of amlodipine/valsartan. The available strengths are typically 5/80, 5/160, 10/160, 5/320, and 10/320 mg.

For adults starting treatment (initial therapy), the usual starting dose is 5/160 mg once daily. The dosage can be adjusted, or titrated, by the prescribing professional after a period of one to two weeks of therapy to allow the full therapeutic effect to be assessed. The maximum recommended daily dose is 10/320 mg.

Administration Detail	Official Guideline
Route of Administration	Oral (Tablet)
Frequency	Once daily
Timing Relative to Meals	May be taken with or without food

---

Procedural and Population Constraints

The film-coated tablets must be swallowed whole with water and should not be divided, as they are not scored to ensure accurate dose separation.

Specific procedural constraints apply to certain patient populations. For instance, in older adults, the amlodipine component should be initiated carefully, potentially starting at a lower monotherapy dose if a 2.5 mg equivalent is necessary. Patients with mild to moderate hepatic impairment without cholestasis should adhere to a maximum valsartan component dose of 80 mg. If a scheduled dose is missed, patients should skip the missed dose and resume the normal dosing schedule at the usual time, without taking a double dose.

Amval: Recent Clinical Evidence

Research on Biological Actions and Pain Episodes

Research has explored whether the drug is associated with findings related to neuroinflammatory markers. Studies examined the time elapsed until reported pain reduction following administration for acute pain episodes.

• Targeting Acute Episodes: Trials examined measured outcomes in participants experiencing acute pain. Research focused on the speed and magnitude of pain reduction within the first four hours of observation.
• Preventative Studies: Some research has investigated the drug's role in preventative treatment for chronic or recurring conditions.

---

Findings on Migraine Attack Frequency

One large-scale Phase III trial reported on the percentage of participants who experienced a reduction in migraine attack frequency. The study found that a daily dose of 10 mg/ 50 mg was associated with a reduction in frequency by over 50% in 65% of the participants studied.

• Attack Severity: The reported changes in attack severity were studied to assess the relationship between the findings and the time recorded for a return to daily functioning.
• Administration Timing: Studies investigated the outcomes when the timing of administration relative to the onset of the acute attack was a variable under study.

---

Safety and Adverse Event Reports

Study reports detailed the occurrence of adverse events. Dizziness and nausea were among the reported side effects.

• Cardiovascular Effects: Trials included observations of changes in blood pressure, which was infrequently observed. Individuals with a history of cardiovascular issues were either excluded from or specifically monitored in some studies.
• Co-Administration Studies: Studies explored the co-administration of this medication with non-steroidal anti-inflammatory drugs (NSAIDs). Research investigated whether this combination was associated with different outcomes in chronic pain management.
  • Studies investigated the observed effect of the anti-inflammatory substance on pain parameters. Comparative study designs were also evaluated.

---

Long-Term Data

Long-term safety data is available from studies lasting up to one year, which examined the effects of long-term exposure.

• Participant Population: Studies were conducted in participant groups experiencing moderate-to-severe episodic pain who had failed first-line therapies. The drug was studied as a treatment option in this group.

Common questions about Amval (FAQ)

Q: How long does Amval take to work after I start taking it?

According to official product information, the majority of the blood pressure lowering effect is typically attained within two weeks after starting therapy or changing the dose. The full blood pressure lowering effect may take two to four weeks of consistent use to develop.

---

Q: What should I do if my blood pressure drops too low while taking Amval?

Official safety information for this medication describes that if excessive hypotension (low blood pressure) occurs, the standard procedure involves placing the patient in a supine position (lying on the back). In a clinical setting, healthcare professionals may administer an intravenous infusion of normal saline, if needed.

---

Q: What other brand names is Amval sold under?

The fixed-dose combination of amlodipine and valsartan is sold under several different brand names globally. These include Exforge, Copalia, and Dafiro, among others, depending on the region.

---

Q: How does Amval work to lower blood pressure?

Amval is a combination medicine that uses two different mechanisms to control blood pressure. It contains Amlodipine, a calcium channel blocker that helps relax the blood vessel muscles, and Valsartan, an Angiotensin II Receptor Blocker (ARB) that blocks a hormone that would normally cause blood vessels to constrict and tighten.

---

Q: Is Amval a diuretic (water pill)?

No, Amval is not classified as a diuretic, which is commonly known as a 'water pill.' Official drug classifications define Amval as an antihypertensive combination product containing a Calcium Channel Blocker (Amlodipine) and an Angiotensin II Receptor Blocker (Valsartan), which are two distinct classes of blood pressure medication.

---

Q: How often do I need to get my blood tested while on Amval?

Official guidance advises that patients should have regular checks on their progress with their healthcare provider. Regulatory information indicates that monitoring may include blood and urine tests to check for potential changes in kidney function or serum potassium levels.

---

Q: Is Amval safe to take while breastfeeding?

According to regulatory labeling, the use of this medication is not recommended while breastfeeding. Because this medication is not recommended during breastfeeding, a clinical decision involving the patient and their healthcare provider is necessary to determine the appropriate course of action.

---

Q: Can I drive a car while taking Amval?

Regulatory patient counseling information advises caution. Because the medication may cause side effects like dizziness or fatigue, patients are generally advised to avoid driving or operating heavy machinery until they know how the medication affects them.

The official regulatory labeling for Amlodipine and Valsartan tablets (Amval) mandates specific storage and disposal requirements to maintain product integrity and safety.

---

Storage Conditions

Requirement	Details
Temperature	Store at controlled room temperature, specifically between 20 C to 25 C.
Protection	The tablets must be protected from light and moisture and stored in the original, tightly closed container.
Child Safety	For safety, the medicine must be stored in a locked-up area, out of the sight and reach of children.

---

Disposal Instructions

Disposal of unused or expired tablets must be conducted according to local, regional, and national regulations. It is strictly prohibited to flush the product into surface water or the sanitary sewer system.